SCM
TIL icon

Silverarc Capital Management’s Instil Bio TIL Stock Holding History

Silverarc Capital Management’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,517
Closed -$708K – 80
2024
Q3 		$708K Buy
+10,517
New +$248K 0.16% 62

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Silverarc Capital Management's TIL Position: Q4 2024 in Review

Silverarc Capital Management sold out of Instil Bio (TIL) in Q4 2024, closing a stake of 10,517 shares — an estimated $708K sold.

Silverarc Capital Management first reported a position in TIL in Q3 2024 and held it in 1 quarter. The position peaked at $708K in Q3 2024. 40 funds tracked by Wall St. Rank hold TIL as of Q4 2024.

  • Silverarc Capital Management reported no remaining Instil Bio position as of Q4 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 10,517 Instil Bio shares in Q4 2024, an estimated $708K.
  • Silverarc Capital Management first reported a position in Instil Bio in Q3 2024 and held it in 1 quarter.
  • Silverarc Capital Management's Instil Bio position peaked at $708K in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Instil Bio as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.